Pharmaceutical News

First-in-Class: Cinda Biotech's TROP-2 ISAC Drug Clinical Trial Application CDE Cinda Biotech's clinical trial application for its first-in-class TROP-2-targeted ISAC drug, IBI-3007, has been accepted. This innovative therapy enhances anti-tumor effects by coupling immune stimulators with antibodies, offering promising efficacy and safety in preclinical studies.
Recent Advances in Targeted Protein Degradation and Four Major Innovative Directions TPD Explore the latest advances in Targeted Protein Degradation (TPD) technology, its diverse strategies, clinical progress, and innovative directions that offer new hope for treating undruggable diseases.
The Legendary Liver Disease Drug Descends from the Pedestal FDA EMA Ocaliva (Obeticholic acid), a once-promising liver disease drug, faces setbacks in both the US and Europe. After failing to secure MASH approval and with declining sales, its future remains uncertain.
Boundless Bio Announces Pipeline and Leadership Updates Boundless Boundless Bio announces updates to its ecDNA-targeted therapy pipeline and leadership changes, including the decision to discontinue BBI-825's clinical trial and focus on new programs expected in 2025.
Merck: Termination of Two Oncology Projects Merck Merck announces the termination of two oncology projects: Vibostolimab (anti-TIGIT) and Favezelimab (anti-LAG-3), citing safety concerns and failure to meet clinical endpoints in key trials.
Best-in-Class GLP-1 Drugs: Who Will Lead the Market? Viking or Amgen? Viking Amgen Weight loss drugs Explore the competition in the GLP-1 drug market, comparing Viking's oral VK2735 and Amgen's long-acting MariTide to Novo Nordisk and Eli Lilly's market leaders in weight loss and diabetes treatment.
GSK IBAT Inhibitor Treatment for PBC-Related Cholestatic Pruritus Phase III Study Success GSK GSK announces positive Phase III results for Linerixibat, an IBAT inhibitor, in treating cholestatic pruritus associated with PBC, showing significant symptom improvement and promising safety data.
MK-3475A-D77 Study Success Merck Merck's Phase III MK-3475A-D77 study shows positive results for subcutaneous pembrolizumab (MK-3475A) compared to intravenous Keytruda, improving patient experience and accessibility for metastatic NSCLC treatment.
Capital Trend! $16.9 Billion Pharma Spin-off Sanofi Sanofi is negotiating the sale of a 50% stake in its consumer health unit Opella to Clayton, Dubilier & Rice for $16.9 billion. Learn more about the spin-off and other recent pharma industry trends.
Johnson & Protagonist's Oral IL23 Psoriasis Phase 3 Success Johnson & Johnson Protagonist therapeutics Johnson & Johnson and Protagonist announce positive Phase 3 results for Icotrokinra (JNJ-2113), an oral IL-23 receptor antagonist for moderate-to-severe plaque psoriasis, achieving significant skin clearance and a $165M milestone payment.